Gene Editing
Gene editing makes precise changes to DNA, the instruction code of life, using tools such as CRISPR that work like molecular scissors and find-and-replace. It can fix a faulty instruction behind a disease, or breed hardier crops. The first CRISPR treatment, for sickle cell disease, is approved: doctors take out a patient's blood stem cells, edit them, and put them back. It costs about $2.2 million per person, and only dozens have received it.
Maturity
Where it feeds in
Where you have already met this
Casgevy, the first CRISPR therapy, was approved in the US in December 2023 at $2.2 million a patient. Each treatment means collecting a patient's stem cells, editing them, and clearing the bone marrow with high-dose chemotherapy before the cells go back in. In all of 2025, 64 people worldwide were infused. The edit works. The pipeline is narrow.
If this moved
If editing could be delivered safely into the body beyond the liver, and paid for, the longevity megatrend would still sit at 1 - held there by brain-computer interfaces and longevity interventions. Food system transformation would stay at 1 on consumption norms.
What to watch for
Casgevy infusion counts in Vertex's quarterly results - 64 in 2025. In-body editing reaching tissues other than the liver in late-stage trials.
Not to be confused with
Gene therapy by virus. Classic gene therapy adds a working copy of a gene; editing changes the patient's own DNA where it sits.
What it is
Making targeted changes to a genome - CRISPR and its successors - in medicine, agriculture and industrial biology.
How it works
- 01A guide is writtenScientists design a short guide RNA that matches the stretch of DNA they want to change.
- 02The guide is paired with an enzymeThe guide is loaded into a Cas enzyme, which does the cutting or the chemical change.
- 03The pair finds its targetThe complex scans the DNA until the guide matches, next to a short marker sequence the enzyme needs.
- 04The DNA is cut or rewrittenCas9 cuts both strands. Newer base and prime editors change letters without a full cut.
- 05The cell repairs itThe cell's own repair system seals the break - disabling a gene, or copying in a supplied correction.
State of play
- The FDA approved Casgevy, the first therapy using CRISPR/Cas9, for sickle cell disease in patients aged 12 and over on 8 December 2023, and for transfusion-dependent beta thalassemia on 16 January 2024 (FDA, 8 Dec 2023; Vertex, 16 Jan 2024).
- Vertex set Casgevy's US wholesale acquisition cost at $2.2 million (Vertex, Form 8-K, 8 Dec 2023).
- In 2025, 147 people had their first cell collection for Casgevy and 64 were infused, 30 of them in the fourth quarter (Vertex, 12 Feb 2026).
- Casgevy revenue was $116 million in 2025 and $76 million in the second quarter of 2026, up 151% on a year earlier (Vertex, 12 Feb 2026; Vertex, Aug 2026).
- Thirty-three US states, the District of Columbia and Puerto Rico joined the Medicaid Cell and Gene Therapy Access Model, covering about 84% of Medicaid beneficiaries with sickle cell disease (CMS, 15 Jul 2025).
- An infant with CPS1 deficiency received the first personalised in-body base-editing therapy, delivered to the liver in lipid nanoparticles (New England Journal of Medicine, 15 May 2025).
Why it matters
It moves biology from reading to writing. The first approved therapies exist, which makes this one of the few frontier technologies in this Compendium with a delivered clinical outcome.
- It is one of the few frontier technologies on this map with an approved treatment that works. The constraint is getting it to patients.
- It feeds longevity, food, zoonotic risk and biodiversity. None moves on it: each is held at 1 or 2 by something else.
- Sixty-four patients in a year, at $2.2 million each, is what cost and clinical load look like together.
What holds it back
Cost and payment
$2.2 million a patient needs a payer willing to pay. Outcomes-based rebates are how US Medicaid is trying.
Clinical load
Stem-cell collection, editing, high-dose chemotherapy and recovery limit how many patients a treatment centre can take.
Delivery
Outside the liver and cells that can be taken out of the body, getting the editor to the right cells remains the hard technical problem.
Governance of heritable edits
Editing embryos is widely prohibited, but enforcement is national.
Terms
- CRISPR-Cas9
- A bacterial defence system adapted to cut DNA at a chosen place.
- Guide RNA
- The short RNA that tells the Cas enzyme where to act.
- PAM
- A short DNA sequence next to the target that the Cas enzyme needs in order to bind.
- Ex vivo therapy
- Cells are taken out of the patient, edited in a lab and put back.
- Base editing
- Changing a single DNA letter chemically, without cutting both strands.
Steepens
| Megatrend | Weight | Role |
|---|---|---|
| Longevity and the Healthspan Gap | large | |
| Food System Transformation | moderate | |
| Zoonotic and Antimicrobial Resistance Risk | moderate | |
| Biodiversity Loss | marginal | marginal: not counted as a weakest link |
The gradient behaves like a sticky rubber band: it is pulled hardest toward the weakest enabler. Marginal links are shown but do not pull.
If this moved one step
Computed from the map as it stands: this score raised from 3 to 4, every other score unchanged. It is arithmetic, not a forecast.
Raised one step on its own, it lifts no megatrend's weakest link; each gradient it feeds still rises a little.
The gradient also rises in
- Food System Transformation2.3/5 , 2.3/5
- Longevity and the Healthspan Gap1.8/5 , 1.8/5
- Zoonotic and Antimicrobial Resistance Risk2.5/5 , 2.6/5
What would change the gradient
Conditional, not predictive. No dates, no probabilities.
- 01In-vivo delivery, the central technical problem
- 02Cost per patient, which decides reach
- 03International governance of heritable editing, currently national and uneven
Common misconception
That the constraint is technical. Delivery to the right cells, cost per patient, and the governance of heritable edits are each further from resolution than the editing itself.
Talin, B. (2026). Gene Editing. The Future Explorer, dataset v0.4.0 (2026-11-16). https://explorer.talin.digital/e/gene-editing/